Characterization of Hospital Admissions During Immune Checkpoint Inhibitor Therapy: Insights From the ICOG Study.
Wiegmann JP, Fröhlich T, Möhn N, Duzzi L, Narten E, Aurich J, Thomas J, Grote-Levi L, Mahjoub S, Berliner D, Wirth T, Golpon H, Bollmann BA, Von Wasilewski I, Gutzmer R, Heidel FH, Skripuletz T, Beutel G, Ivanyi P; ICOG‐CCCH (Immune Cooperative Oncology Group, Comprehensive Cancer Center Hannover).
Wiegmann JP, et al. Among authors: thomas j.
Cancer Med. 2025 Feb;14(3):e70582. doi: 10.1002/cam4.70582.
Cancer Med. 2025.
PMID: 39865401
Free article.